- Home
- ANIP vs OMCL Comparison
ANIP vs OMCL Comparison
Compare ANIP & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- OMCL
- Stock Information
- Founded
- ANIP 2001
- OMCL 1992
- Country
- ANIP United States
- OMCL United States
- Employees
- ANIP N/A
- OMCL N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- ANIP Health Care
- OMCL Technology
- Exchange
- ANIP Nasdaq
- OMCL Nasdaq
- Market Cap
- ANIP 1.3B
- OMCL 1.3B
- IPO Year
- ANIP N/A
- OMCL 2001
- Fundamental
- Price
- ANIP $63.35
- OMCL $28.49
- Analyst Decision
- ANIP Strong Buy
- OMCL Buy
- Analyst Count
- ANIP 8
- OMCL 6
- Target Price
- ANIP $80.13
- OMCL $44.83
- AVG Volume (30 Days)
- ANIP 292.6K
- OMCL 564.3K
- Earning Date
- ANIP 08-05-2025
- OMCL 07-31-2025
- Dividend Yield
- ANIP N/A
- OMCL N/A
- EPS Growth
- ANIP N/A
- OMCL N/A
- EPS
- ANIP N/A
- OMCL 0.45
- Revenue
- ANIP $674,068,000.00
- OMCL $1,135,755,000.00
- Revenue This Year
- ANIP $30.17
- OMCL $3.84
- Revenue Next Year
- ANIP $7.69
- OMCL $4.07
- P/E Ratio
- ANIP N/A
- OMCL $64.51
- Revenue Growth
- ANIP 30.27
- OMCL 3.00
- 52 Week Low
- ANIP $52.50
- OMCL $22.66
- 52 Week High
- ANIP $77.00
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- ANIP 53.20
- OMCL 41.38
- Support Level
- ANIP $61.18
- OMCL $30.73
- Resistance Level
- ANIP $64.45
- OMCL $32.05
- Average True Range (ATR)
- ANIP 1.84
- OMCL 0.83
- MACD
- ANIP 0.63
- OMCL -0.14
- Stochastic Oscillator
- ANIP 76.59
- OMCL 0.97
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.